Murex hiv 1.2 o hiv eia

Blood specimens were collected from consenting participants and tested at the National HIV Reference Laboratory in Nairobi for HIV antibodies using enzyme immunoassays (EIA) [Vironostika HIV-1/2 UNIF II Plus O EIA (bioMérieux, Marcy I’Etoile, France) as the screening assay and Murex HIV.1.2.O HIV EIA (DiaSorin, SpA, Saluggia, Italy) as the confirmatory assay]. Laboratory-based test results were not returned to participants. However, participants could learn their HIV status in privacy of their homes through home-based testing and counseling using the national HIV testing guidelines for rapid HIV testing.¹³ HIV testing and counseling was conducted by trained home-based testing and counseling service providers who were a part of the survey team. Referrals for follow-up care were provided where needed.

We asked women for their verbal consent to collect a blood sample for biologic testing at the National HIV Reference Laboratory (NHRL) in Nairobi. We tested blood specimens for HIV antibody and if positive, HIV RNA concentration. We tested all specimens for HIV antibody [Vironostika HIV-1/2 UNIF II Plus O Enzyme Immunoassay (EIA) assay; bioMérieux SA, Marcy l’Etoile, France] and confirmed HIV antibody-positive results with the Murex HIV.1.2.O HIV EIA (DiaSorin, SpA, Saluggia, Italy). Repeat testing was done for discordant results and if results remained discordant, final results were obtained using polymerase chain reaction (Cobas Amplicor HIV-1 Monitor Test, v1.5; Roche Molecular Diagnostics, Pleasanton, CA). We tested all HIV-positive specimens for HIV RNA concentration (Abbott m2000 Real-Time HIV-1 assay; Abbott Park, IL). Virologic suppression was defined as HIV RNA concentration <1000 copies per milliliter.